Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Esther M. Bowie MD Advisory Board

Stephanie Watson OAM, BSc, MBBS, FRANZCO, PhD, GAICD, FARVO Advisory Board

Aparna Ramasubramanian MD Advisory Board

See All Experts

featured

Published in Eye Care

Journal Scan / Research · April 18, 2022

Risk of Ocular Adverse Events Associated With the Use of PDE5 Inhibitors in Men in the US

JAMA Ophthalmology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

JAMA Ophthalmology

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US

JAMA Ophthalmol 2022 Apr 07;[EPub Ahead of Print], M Etminan, M Sodhi, FS Mikelberg, D Maberley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Risk of Ocular Adverse Events Associated With the Use of PDE5 Inhibitors in Men in the US

Additional Info

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US

Further Reading

Final Note From the Eye Care Editors

Pars Plana Vitrectomy for the Treatment of Vitreous Amyloid in Patients With Hereditary Transthyretin Amyloidosis

Optimizing Open-Angle Glaucoma Risk Assessment in Patients With Retinal Vein Occlusions

Midterm Survival Results of PreserFlo MicroShunt Implantation in a Real-World Setting

"Triple-Layer Sign": An OCT Signature for the Detection of Non-Exudative Macular Neovascularization

Disease Progression of Pentosan Polysulfate Maculopathy After Drug Cessation

Translating Ophthalmic Medical Jargon Using Artificial Intelligence

Surgical Costs of Enucleation vs Plaque Brachytherapy for Intraocular Malignancies

Evaluation of Peripheral Blood Inflammatory Biomarkers in Sickle Cell Disease With and Without Retinopathy

Visual Recovery After Oral High-Dose Methylprednisolone in Acute Inflammatory Optic Neuropathy

Social Factors Associated With the Risk of Glaucoma Suspect Conversion to Glaucoma

Recently Updated